Insights › Likitanci da magunguna › November 13, 2026
Likitanci da magunguna · Bayanan hukuma

EMA ta ba da shawarar amincewa da Baxfendy (baxdrostat) don hawan jini

European Union EMA (New human medicines) An wallafa:

Kwamitin CHMP na EMA ya amince da ra'ayi mai kyau a ranar 12 ga Nuwamba 2026 yana ba da shawarar izinin tallace-tallace don Baxfendy (baxdrostat), wanda AstraZeneca AB ta haɓaka. Wannan magani mai dauke da baxdrostat an nuna shi don magance marasa lafiya da ke da hawan jini na arterial hypertension. Yana gabatar da sabon tsari don sarrafa hawan jini.

Asalin tushe
Karanta tushen — ema.europa.eu ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Likitanci da magunguna

Duba komai a cikin Likitanci da magunguna →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.